The place of radiotherapy for localized invasive bladder cancer

Urologic Oncology

Volumn 4, Issue 4-5, 1998, Pages 145-153

  Tsujii, H ^a   Gospodarowicz, M K ^b   Bolla, M ^c   Fujita, K ^d   Hudson, M'Liss ^e   Mitsuhashi, N ^f   Roberts, J T ^g   Shimazaki, J ^h  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Department of Radiotherapy ^*  (France)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GUNMA UNIVERSITY   (Japan)

^g NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^h CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

BLADDER CANCER; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CYSTECTOMY; ELECTRON BEAM; HUMAN; INTRAOPERATIVE PERIOD; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; URINARY TRACT CANCER;

EID: 0345085547     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(99)00014-9     Document Type: Conference Paper

References (90)

1. [1] Colvett KT, Althausen AF, Bassil B, et al. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. J Surg Oncol 1996;63:201-8.
2. [2] Koiso K, Shipley W, Keuppens F, et al. The status of bladder-preserving therapeutic strategies in the management of patients with muscle-invasive bladder cancer. Int J Urol 1995;2(suppl. 2):49-57.
3. [3] Gospodarowicz MK, Quilty PM, Scalliet P, et al. The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol 1995; 2(suppl. 2):41-8.
4. [4] Hall MC, Dinney CP. Radical cystectomy for stage T3b bladder cancer. Semin Urol Oncol 1996;14:73-80.
5. [5] Wishnow KI, Levinson AK, Johnson DE, et al. Stage B transitional cell carcinoma of the bladder highly curable by radical cystectomy. Urology 1992;39:12-6.
6. [6] Pagano F, Bassi P, Galleti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes, and metastasis classification. J Urol 1991;145:45-50.
7. [7] Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in the management of invasive bladder cancer. J Urol 1984; 131:1069-77.
8. [8] Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int Radiat Oncol Biol Phys 1994;30:267-77.
9. [9] Vale JA, A'Hern RP, Liu K, et al. Predicting the outcome of radical radiotherapy for invasive bladder cancer. Eur Urol 1993;24:48-51.
10. [10] Porter AT. The role of radiotherapy in the treatment of muscle invasive bladder cancer. Prog Clin Biol Res 1990;353:23-34.
11. [11] Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25: 783-90.
12. [12] Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 1996;23:621-32.
13. [13] Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119-26.
14. [14] Prout, GR Jr, Shipley WU, Kaufman DS, et al. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J Urol 1990;144:1128-34.
15. [15] Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird, JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 1993;329:1377-82.
16. [16] Shipley WU, Kaufman DS, Griffin PP, Althausen AF, Heney NM, Prout GR Jr. Radiochemotherapy for invasive carcinoma of the bladder. Recent Results in Cancer Res 1993;126:207-16.
17. [17] Duchesne GM. Radical treatment for primary bladder cancer: where are we and where do we go from here? A review. Clin Oncol 1994;6:121-6.
18. [18] Caffo O, Fellin G, Graffer U, Luciani L. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer 1996;78:1089-97.
19. [19] Mommsen S, Jakobsen A, Sell A. Quality of life in patients with advanced bladder cancer. Scand J Urol Nephrol 1989;145(suppl.):743.
20. [20] Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J Urol 1995;154:2059-63.
21. [21] Cole CJ, Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. Int J Radiat Oncol Biol Phys 1995;32:331-40.
22. [22] Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996;14:2901-7.
23. [23] Plataniotis G, Michalopoulos E, Kouvaris J, Vlahos L, Papavasiliou C. A feasibility study of partially accelerated radiotherapy for invasive bladder cancer. Radiother Oncol 1994;33:84-7.
24. [24] Zietman AL, Shipley WU, Kaufman DS. The combination of cisplatin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. Int J Radiat Oncol Biol Phys 1993;27:161-70.
25. [25] Blandy J, England H, Evans SJW, et al. T3 bladder cancer - the case for salvage cystectomy. Br J Urol 1980;52:506-10.
26. [26] Abratt RP, Wolson JA, Pontin AR, Barnes RD. Salvage cystectomy after radical irradiation for bladder cancer-prognostic factors and complications. Br J Urol 1993;72:756-60.
27. [27] Tomic R, Granfors T, Modig H. Morbidity after preoperative radiotherapy and cystectomy in patients with bladder cancer. Scand J Urol Nephrol 1997;31:149-53.
28. [28] Smaaland R, Akslen LA, Tonder B, Mehus A, Lote K, Albrektsen G. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol 1991;67:61-9.
29. [29] Salminen E. External beam radiation treatment of urinary bladder carcinoma. Acta Oncol 1990;29:909-10.
30. [30] Jahnson SJ, Pedersen J, Westman G. Bladder carcinoma: a 20-year review of radical radiation therapy. Radiother Oncol 1991;22:111-7.
31. [31] Greven KM, Solin LJ, Hanks GE. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation. Cancer 1990; 65:908-12.
32. [32] Goffinet DR, Schneider MJ, Glatstein EJ, et al. Bladder cancer: results of radiation therapy in 384 patients. Radiology 1975;117:149-53.
33. [33] Edsmyr F, Andersson L, Esposti PL, Littbrand B, Nilsson B. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol 1985;4:197-203.
34. [34] Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448-54.
35. [35] Raghavan D, Huben R. Management of bladder cancer. Curr Probl Cancer 1995;19:1-64.
36. [36] Jenkins B, Caulfield M, Fowler CG, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988;62:343-6.
37. [37] Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995;31:247-54.
38. [38] Quilty PM, Kerr GR, Duncan W. Prognostic indices for bladder cancer: an analysis of patients with transitional cell carcinoma of the bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol 1986;7:311-21.
39. [39] De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol 1995;36:183-8.
40. [40] Sell A, Jakobsen A, Nerstrom B. Treatment of advanced bladder cancer category T2, T3, T4a. Scand J Urol Nephrol 1991;138(suppl.):193-201.
41. [41] Pollack A, Zagars GZ. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996;14:86-95.
42. [42] Kachnic LA, Kaufman DS, Zietman AL, et al. Selective bladder preservation by combined modality therapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 1995;32(suppl.1):271.
43. [43] Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331: 1259-64.
44. [44] Ogura K, Habuchi T, Yamada H, Ogawa O, Yoshida O. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity. Int J Urol 1995;2:302-8.
45. [45] Wu CS, Pollack A, Czerniak B, et al. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology 1996;47:305-10.
46. [46] Lopez-Beltran A, Croghan GA, Croghan I, Matilla A, Gaeta JF. Prognostic factors in bladder cancer. A pathologic, immunohistochemical, and DNA flow-cytometric study. Am J Clin Pathol 1994;102:109-14.
47. [47] Ye DW, Zheng JF, Qian SX, Ma YJ. Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. Urol Res 1993;21:39-43.
48. [48] Bilim V, Kawasaki T, Takahashi K. Significance of wild type p53 and p21 for cell cycle arrest in G2 phase in response to genotoxic stress induced by anticancer drug adriamycin. J Urol 1997;157(suppl. 4):27.
49. [49] Kawasaki T, Tomita Y, Bilim V, et al. p21/WAF1/CIP1 is responsible for apoptosis induced by DNA damaging agents in human bladder cancer cell lines. J Urol 1997;157(suppl. 4):27.
50. [50] Granfors T, Duchek M, Tomic R, et al. Predictive value of DNA ploidy in bladder cancer treated with preoperative radiation therapy and cystectomy. Scand J Urol Nephrol 1996;38:281-5.
51. [51] Goldobenko GV, Matveev BP, Shipilov VI, Klimakov BD, Tkachev SI. Radiation treatment of bladder cancer using different fractionation regimens. Med Radiol Mosk 1991;36:14-6.
52. [52] Naslund I, Littbrand B. Hyperfractionated radiotherapy of bladder cancer: a ten-year follow-up of a randomized clinical trial. Acta Oncol 1994;33:397-402.
53. [53] Stuschke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Biol Oncol Phys 1997;37:259-67.
54. [54] Maciejewski B, Majewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21: 163-70.
55. [55] Horwich A, Pendlebury S, Dearnaley DP. Organ conservation in bladder cancer. Eur J Cancer 1995;31(suppl. 5):208.
56. [56] Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27:131-46.
57. [57] Duncan W, Quilty PM. The results of series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage x-ray therapy. Radiother Oncol 1986;7:299-310.
58. [58] Salminen E. Unconventional fractionation for palliative radiotherapy of urinary bladder cancer. Acta Oncol 1992;31:449-54.
59. [59] Rostom AY, Tahir S, Gershuny AR, Kandil A, Folkes A, White WF. Once weekly irradiation for carcinoma of the bladder. Int J Radiat Biol Oncol Phys 1996;35:289-92.
60. [60] Letocha H, Malmstrom PU, Rikner G, Nilsson S. Combined systemic chemotherapy and irradiation of muscle-invasive transitional cell carcinoma of the urinary bladder. Acta Oncol 1994;33:195-200.
61. [61] Parsons JT. Conservation treatment of muscle-invasive bladder cancer using radiotherapy. Front Radiat Ther Oncol 1993;27:143-65.
62. [62] Larsen LE, Engelholm SA. The value of three-dimensional radiotherapy planning in advanced carcinoma of the urinary bladder based on computed tomography. Acta Oncol 1994;33:655-9.
63. [63] Cole DJ, Durrant KR, Roberts JT, Dawes PJ, Yosef H, Hopewell JW. A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol 1992;65:792-8.
64. [64] Quilty PM, Duncan W. Primary radical radiotherapy for T3 transitional cell cancer of the bladder: an analysis of survival and control. Int J Radiat Oncol Biol Phys 1986;12:853-60.
65. [65] Yu WS, Sagerman RH, Chung CT, Dalal PS, King GA. Bladder carcinoma. Experience with radical and preoperative radiotherapy in 421 patients. Cancer 1985;56:1293-9.
66. [66] Marks LB. Treatment time in bladder cancer. Radiother Oncol 1992; 23:269-70.
67. [67] Fossa SD, Ous S, Knudsen OS. Radical irradiation of T2 and T3 bladder carcinoma. A retrospective investigation. Acta Radiol Oncol 1985;24:497-501.
68. [68] Slack NH, Bross IDJ, Prout GR Jr. Five-year follow-up results of a collaborative study of therapies for carcinoma of the bladder. J Surg Oncol 1977;9:393-405.
69. [69] Crawford ED, Das S, Smith JA Jr. Preoperative radiation therapy in the treatment of bladder cancer. Urol Clin North Amer 1987;14: 781-7.
70. [70] Lybeert ML, Ribot JG, de Neve W, Goor C, Crommelin MA. Carcinoma of the urinary bladder: long-term results of interstitial radiotherapy. Bull Cancer Radiother 1994;81:33-40.
71. [71] Rozan R, Albuisson E, Donnarieix D, et al. Interstitial iridium-192 for bladder cancer (a multicentric survey: 205 patients). Int J Radiat Oncol Biol Phys 1992;24:469-77.
72. [72] van der Werf-Messing BHP. Interstitial radiation therapy of carcinoma of the urinary bladder. Endocurie Hypertherm Oncol 1982;2:67-76.
73. [73] Wijnmaalen A, van der Werf-Messing B. Factors influencing the prognosis in bladder cancer. Int J Radiat Oncol Biol Phys 1986;12: 559-65.
74. [74] Fujita K. Intraoperative radiation for bladder cancer preserving the urinary bladder. Proc Int Cancer Congress 1994:2141-3.
75. [75] Shipley WU, Kaufman SD, Prout GR Jr. Intraoperative radiation therapy in patients with bladder cancer. A review of techniques allowing improved tumor doses and providing high cure rates without loss of bladder function. Cancer 1987;60:1485-8.
76. [76] Matsumoto K, Kakizoe T, Mikuriya S, Tanaka T, Kondo I, Umegaki Y. Clinical evaluation of intraoperative radiotherapy for carcinoma of the urinary bladder. Cancer 1981;47:509-13.
77. [77] Calvo FA, Aristu JJ, Abuchaibe O, et al. Intraoperative and external preoperative radiotherapy in invasive bladder cancer: effect of neoadjuvant chemotherapy in tumor downstaging. Am J Clin Oncol 1993; 16:61-6.
78. [78] Leith JT. Heavy-ion radiotherapy: normal tissue studies. Adv Radiol Bio 1983;10:191-236.
79. [79] Tsujii H, Akaza M, Ohtani N, et al. Preliminary results of bladder-preserving therapy with definitive radiotherapy and intaarterial infusion of chemotherapy. Strahlenther Onkol 1994;170:531-7.
80. [80] Tsujii H, Tsuji H, Inada T, et al. Clinical results of fractionated proton therapy. Int J Radiat Oncol Biol Phys 1993;25:49-60.
81. [81] Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990;322:1129-38.
82. [82] Given RW, Parsons JT, McCarley D, Wajsman Z. Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up. Urology 1995;46:499-504.
83. [83] Douglas RM, Kaufman DS, Zietman AL, Althausen AF, Heney NM, Shipley WU. Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. Semin Oncol 1996;23:614-20.
84. [84] Dunst J, Sauer R, Schrott KM, Kuhn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys 1994;30:261-6.
85. [85] Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys 1997;39:937-43.
86. [86] Loehrer PS, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, visblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
87. [87] Gospodarowicz MK, Rider WD, Keen C, et al. Bladder cancer: Long-term follow-up results of patients treated with radical radiation. Clin Oncol 1991;3:155-61.
88. [88] Fossa SD, Woehre H, Aass N, et al. Definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 1993;72:3036-43.
89. [89] Miller LS. Bladder cancer: Superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1977;30:973-80.
90. [90] Bloom HJG, Hendry WF, Skeet RG, et al. Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 1982;54:136-51.